Vertex Pharmaceuticals Inc (VRTX) stock
VRTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 15/3028% above fair value
$542.62−4.41 (-0.81%)
Close on Nov 12, 2026Market cap $137.53BP/E 31.6Yield –
Vertex Pharmaceuticals r&d expenses
Research and development expenses are spending on new products and technology.
Vertex Pharmaceuticals's R&D Expenses for the twelve months ending Jun 30, 2026 was $3.91B, up 1.9% year over year. For fiscal 2025 it was $3.91B, up 7.7% from the year before. Over ten years it grew 14.7% a year on average. The highest annual figure on record is $3.91B in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.91B | +7.7% |
| FY2024 | Dec 31, 2024 | $3.63B | +14.8% |
| FY2023 | Dec 31, 2023 | $3.16B | +24.5% |
| FY2022 | Dec 31, 2022 | $2.54B | +31.1% |
| FY2021 | Dec 31, 2021 | $1.94B | +17.8% |
| FY2020 | Dec 31, 2020 | $1.64B | -6.2% |
| FY2019 | Dec 31, 2019 | $1.75B | +23.9% |
| FY2018 | Dec 31, 2018 | $1.42B | +6.9% |
| FY2017 | Dec 31, 2017 | $1.32B | +26.4% |
| FY2016 | Dec 31, 2016 | $1.05B | +5.2% |
| FY2015 | Dec 31, 2015 | $995.92M | +16.4% |
| FY2014 | Dec 31, 2014 | $855.51M | -3.0% |
| FY2013 | Dec 31, 2013 | $882.10M | +15.2% |
| FY2012 | Dec 31, 2012 | $765.91M | +8.2% |
| FY2011 | Dec 31, 2011 | $707.71M | +11.0% |
| FY2010 | Dec 31, 2010 | $637.42M | +15.8% |
| FY2009 | Dec 31, 2009 | $550.27M | +6.5% |
| FY2008 | Dec 31, 2008 | $516.91M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $993.80M | +1.6% |
| Q1 FY2026 | Mar 31, 2026 | $961.60M | -1.8% |
| Q4 FY2025 | Dec 31, 2025 | $973.70M | -2.5% |
| Q3 FY2025 | Sep 30, 2025 | $977.70M | +11.6% |
| Q2 FY2025 | Jun 30, 2025 | $978.40M | +1.2% |
| Q1 FY2025 | Mar 31, 2025 | $979.70M | +24.2% |
| Q4 FY2024 | Dec 31, 2024 | $998.70M | +21.1% |
| Q3 FY2024 | Sep 30, 2024 | $875.90M | +8.1% |
| Q2 FY2024 | Jun 30, 2024 | $966.60M | +23.0% |
| Q1 FY2024 | Mar 31, 2024 | $789.10M | +6.3% |
| Q4 FY2023 | Dec 31, 2023 | $824.60M | +18.8% |
| Q3 FY2023 | Sep 30, 2023 | $810.00M | +25.6% |
| Q2 FY2023 | Jun 30, 2023 | $785.70M | +30.9% |
| Q1 FY2023 | Mar 31, 2023 | $742.60M | +23.5% |
| Q4 FY2022 | Dec 31, 2022 | $694.10M | +22.2% |
| Q3 FY2022 | Sep 30, 2022 | $645.00M | +38.1% |
| Q2 FY2022 | Jun 30, 2022 | $600.10M | +33.7% |
| Q1 FY2022 | Mar 31, 2022 | $601.10M | +31.8% |
| Q4 FY2021 | Dec 31, 2021 | $567.80M | +21.7% |
| Q3 FY2021 | Sep 30, 2021 | $467.00M | -5.4% |
| Q2 FY2021 | Jun 30, 2021 | $448.70M | +6.6% |
| Q1 FY2021 | Mar 31, 2021 | $456.00M | +1.7% |
| Q4 FY2020 | Dec 31, 2020 | $466.58M | -2.8% |
| Q3 FY2020 | Sep 30, 2020 | $493.50M | -11.2% |
| Q2 FY2020 | Jun 30, 2020 | $420.93M | +11.0% |
| Q1 FY2020 | Mar 31, 2020 | $448.53M | +32.1% |
| Q4 FY2019 | Dec 31, 2019 | $480.01M | +9.6% |
| Q3 FY2019 | Sep 30, 2019 | $555.95M | +68.2% |
| Q2 FY2019 | Jun 30, 2019 | $379.09M | +12.3% |
| Q1 FY2019 | Mar 31, 2019 | $339.49M | +9.3% |
| Q4 FY2018 | Dec 31, 2018 | $437.88M | +42.8% |
| Q3 FY2018 | Sep 30, 2018 | $330.51M | -27.4% |
| Q2 FY2018 | Jun 30, 2018 | $337.53M | +16.6% |
| Q1 FY2018 | Mar 31, 2018 | $310.55M | +13.5% |
| Q4 FY2017 | Dec 31, 2017 | $306.66M | +23.4% |
| Q3 FY2017 | Sep 30, 2017 | $454.95M | +67.0% |
| Q2 FY2017 | Jun 30, 2017 | $289.45M | – |
| Q1 FY2017 | Mar 31, 2017 | $273.56M | – |
| Q4 FY2016 | Dec 31, 2016 | $248.45M | – |
| Q3 FY2016 | Sep 30, 2016 | $272.37M | – |
See a number that looks wrong?